다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Clinical medicine : journal of the Royal College of Physicians of London, v.20 no.3, 2020년, pp.278 - 281
Sturrock, Beattie RH (ABrighton and Sussex Medical School, Brighton UK and Royal Sussex County Hospital, Brighton, UK) , Chevassut, Timothy JT (BBrighton and Sussex Medical School, Brighton UK and consultant haematologist, Royal Sussex County Hospital, Brighton, UK)
AI-Helper
The novel coronavirus SARS-CoV-2, causing the disease COVID-19, first emerged in Wuhan, China in December 2019 and has now spread to 203 countries or territories, infected over 2 million people and caused over 133,000 deaths. There is an urgent need for specific treatments. One potential treatment i...
World Health Organization
N Engl J Med Zhu 382 727 2020 10.1056/NEJMoa2001017 A novel coronavirus from patients with pneumonia in China, 2019
World Health Organization
JAMA Paules 323 707 2020 10.1001/jama.2020.0757 Coronavirus infections - more than just the common cold
Nat Rev Microbiol De Wit 14 523 2016 10.1038/nrmicro.2016.81 SARS and MERS: recent insights into emerging coronaviruses
Coronavirus disease (COVID-19) pandemic World Health Organization 2020
Lancet Huang 395 497 2020 10.1016/S0140-6736(20)30183-5 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Lancet Chen 395 507 2020 10.1016/S0140-6736(20)30211-7 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
JAMA Wang 323 1061 2020 10.1001/jama.2020.1585 Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China
Drug Discov Ther Dong 14 58 2020 10.5582/ddt.2020.01012 Discovering drugs to treat coronavirus disease 2019 (COVID-19)
J Antimicrob Chemother Zhou 2020 COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
J Antimicrob Chemother Al-Bari 70 1608 2015 10.1093/jac/dkv018 Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases
Antimicrob Agents Chemother Keyaerts 53 3416 2009 10.1128/AAC.01509-08 Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice
Biochem Biophys Res Commun Keyaerts 323 264 2004 10.1016/j.bbrc.2004.08.085 In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Virol J Vincent 2 69 2005 10.1186/1743-422X-2-69 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Antivir Chem Chemother Barnard 17 275 2006 10.1177/095632020601700505 Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice
Lancet Infect Dis Savarino 3 722 2003 10.1016/S1473-3099(03)00806-5 Effects of chloroquine on viral infections: An old drug against today's diseases
Int J Antimicrob Agents Rolain 30 297 2007 10.1016/j.ijantimicag.2007.05.015 Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century
Proc Natl Acad Sci USA Simmons 101 4240 2004 10.1073/pnas.0306446101 Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry
Cell Discov Liu 6 16 2020 10.1038/s41421-020-0156-0 Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
Nat Rev Rheumatol Schrezenmeier 16 155 2020 10.1038/s41584-020-0372-x Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
Cell Res Wang 30 269 2020 10.1038/s41422-020-0282-0 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Clin Infect Dis Yao 2020 10.1093/cid/ciaa237 In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Molecules Nqoro 22 2268 2017 10.3390/molecules22122268 Quinoline-based hybrid compounds with antimalarial activity
Chin Med J (Engl) Fan 2020 10.1097/CM9.0000000000000797 Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model
Biosci Trends Gao 14 72 2020 10.5582/bst.2020.01047 Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
J Crit Care Cortegiani 2020 A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
J Zhejiang Univ (Med Sci) Chen 2020 A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)
Int J Antimicrob Agents Gautret 2020 10.1016/j.ijantimicag.2020.105949 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Trump
Int J Antimicrob Agents Colson 2020 10.1016/j.ijantimicag.2020.105923 Chloroquine for the 2019 novel coronavirus SARS-CoV-2
Ann Rheum Dis Aviña-Zubieta 57 582 1998 10.1136/ard.57.10.582 Long term effectiveness of antimalarial drugs in rheumatic diseases
Ann Rheum Dis Ruiz-Irastorza 69 20 2010 10.1136/ard.2008.101766 Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review
Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 43 185 2020
Lupus Foundation of America
Int J Antimicrob Agents Sahraei 2019 Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine
Lancet Glob Health Mitjà 2020 10.1016/S2214-109X(20)30114-5 Use of antiviral drugs to reduce COVID-19 transmission
Clin Med Lake 20 124 2020 10.7861/clinmed.2019-coron What we know so far: COVID-19 current clinical knowledge and research
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.